药物警戒中的因果关系评估:仍是挑战
本文讨论药物警戒中因果关系的判定难题,指出因果判断应以患者而非药品为中心,需考虑多重因果向量。药物警戒旨在识别统计离群者甚至个体信号,需更多数据、分析与临床参与;提高假设透明度和匿名病例数据可获取性有助于汇聚专业力量并降低临床负担与社会成本。
要点
- 因果判断应以患者为中心,而非仅关注药品本身。
- 需考虑多重因果向量,包括用药错误和已知风险因素识别不足。
- 更多数据、分析与临床参与可提升因果信号识别与管理。
核心结论
- 药物警戒中的因果关系判定复杂且耗时,需从患者背景而非药品产品角度审视。
- 关注统计离群者甚至个体伤害经历可形成因果信息,帮助预防更多风险患者暴露或早期识别与管理药物相关伤害。
主要发现
- 因果关系复杂,应考虑多重因果向量,包括用药错误和导致治疗不良结局的诸多其他因素,如未能识别已知风险因素。
- 药物警戒主要关注统计离群者中的小部分人群甚至个体,其伤害经历可共同形成因果信息。
临床怎么用
- 因果评估需投入更多时间、更多数据、更多分析,并让患者和临床更多参与报告有用的临床细节。
- 回归收集更多可能与因果相关的病例数据可以是有选择性的,不一定倒退或成本过高。
- 提高假设透明度并提供匿名病例数据,可让更多专业知识参与评估与假设检验。
- 提供更完整有用的信息应能减少不良患者结局带来的临床负担及社会总体成本。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Causality in pharmacovigilance is a difficult and time consuming exercise. This paper presents the challenges in determining causation by drug therapy. The first is that causation is complex and needs to be viewed from the context of the patient treated, rather than the drug product. Multiple causal vectors should be considered if we are to tackle the many issues involved in, for example, medication error and the many other factors that lead to bad outcomes from therapy, including failure to recognise known risk factors. The aim of pharmacovigilance is not only a bureaucratic exercise in public health norms, but is mainly concerned with small minorities of statistical outliers-and even individuals-whose experiences from harms may together form messages about causation that will prevent further at-risk patients from exposure, or at least assist with earlier recognition of drug-related harm and better management of such harm. This requires more time, more data, more analysis and more patient and clinical involvement in reporting useful clinical detail. The paradigm shift back towards gathering more case data relating to possible causation can be selective and would not be just retrogressive, nor necessarily too costly. Greater transparency of hypotheses and availability of anonymised case data will enrol more expertise into evaluations and hypothesis testing, and the provision of more complete and useful information should reduce clinical burdens from bad patient outcomes as well as their overall costs to society.
引用
- Ralph Edwards I. Causality Assessment in Pharmacovigilance: Still a Challenge. Drug Saf. 2017. PMID: 28247280. doi:10.1007/s40264-017-0509-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。